Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with ...

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Recent Study Testing International Formulation Shows Significant Increase in GLP-1 HormoneSALT LAKE CITY, Feb. 04, 2025 ...